"I want to preserve the fantastic work culture that we have built here over the years. Keeping this culture intact would be our priority in any M&A deal."
"Mexico as a country has a very matured and experienced manufacturing industry and has the right competitive advantages to become the first supplier for various markets in the US."
"With US$508 million left to spend on the Media Luna project south of the river, we have a strong, cash-producing asset at ELG that is financing the construction of our future."
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.